Related references
Note: Only part of the references are listed.Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging
Eugene Shkolyar et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report
Jun Fan et al.
DIAGNOSTIC PATHOLOGY (2020)
ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
Yuanyuan Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Salivary Secretory Carcinoma Harboring a Novel ALK Fusion
Eiichi Sasaki et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
ALK rearrangement in a gastrointestinal stromal tumour of the small bowel
Lei Zhao et al.
HISTOPATHOLOGY (2020)
Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
Annalisa Astolfi et al.
FRONTIERS IN ONCOLOGY (2020)
Morphological features useful in the differential diagnosis between undifferentiated carcinoma and gastrointestinal stromal tumor
Bohuslava Vankova et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2020)
Genetic Characterization of Molecular Targets in Korean Patients with Gastrointestinal Stromal Tumors
Joonhong Park et al.
JOURNAL OF GASTRIC CANCER (2020)
Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA
Patrick Mayr et al.
LANGENBECKS ARCHIVES OF SURGERY (2019)
A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma
Xiaodong Fei et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel KIF5B-ALK Fusion Oncokinase
Naoki Shimizu et al.
ANTICANCER RESEARCH (2019)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Hao Huang
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
Maria A. Pantaleo et al.
CANCER MEDICINE (2015)
An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall
Tatsuki R. Kataoka et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations
Sosipatros A. Boikos et al.
ENDOCRINE (2014)
A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
Sebastian Huss et al.
MODERN PATHOLOGY (2013)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients
Jing Gao et al.
MEDICAL ONCOLOGY (2012)
A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer
Shivashankar H. Nagaraj et al.
BMC SYSTEMS BIOLOGY (2011)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
EML4-ALK fusion lung cancer:: A rare acquired event
Sven Perner et al.
NEOPLASIA (2008)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
B Lawrence et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
